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I N DESCRIBING the Australian trials, Sheil complimented those in the Sandoz 
Corporation for their professionalism and 
integrity, a remark that is germane to the 
Houston meeting. The program was devel-
oped not as a triumphant forum but in order to 
assess the problems as well as the prospects 
that transplantation will face in the new era 
which will be started this summer with the 
general availability of cyclosporine. A good 
look has been taken at this new pharmacologic 
emperor without its clothes, and cyclosporine 
has withstood the scrutiny quite well. 
The reason for the excitement can be stated 
simply. With cyclosporine, it has been possible 
to transplant some of the solid organs with a 
success not previously possible and to carry 
out other kinds of solid organ transplantation 
that were previously beyond our grasp. Such 
successes provided half of the clinical story of 
this meeting. The other half concerned the 
price for these increased expectations. 
The most extensive experience has been 
with the kidney, and certainly the most mean-
ingful data have come from cadaveric trans-
plantation. One-year graft survival after 
familial transplantation in good centers has 
been so high (greater than 70%) for almost 
two decades that statistically significant fur-
ther increases with a new form of immunosup-
pression would be difficult to achieve. Thus, 
the superior results from Kyoto, Japan, with 
greater than 90% I-year graft survival after 
parent-to-offspring transplantation under cy-
c1osporine-steroid therapy were not consid-
ered better than those obtainable with conven-
tional treatment in this group's historical 
experience. The same reservation applied to 
about 45% of the cases in the Minnesota 
randomized trial, in which the I-year graft 
survival after consanguineous transplantation 
was better than 85% with both cyclosporine-
steroid therapy and with the combined use of 
azathioprine, prednisone, and ALG. 
Cadaveric renal transplantation under 
cyclosporine-steroid therapy (with a variable 
steroid component) versus conventional ther-
apy were compared in multicenter trials in 
Europe and in Canada. Both studies showed a 
20% I-year advantage in the cyclosporine 
group. Adverse factors for the cyclosporine 
limb in the Canadian trials were said to be 
machine perfusion of the renal grafts for more 
than 24 hr or an ischemia time of more than 
45 min during the construction of vascular 
anastomoses. It was interesting that one of the 
participating teams, from the Mount Sinai 
Hospital, Toronto, presented what amounted 
to a minority Canadian report. Their preexist-
ing policy had been to treat cadaveric kidney 
recipients with azathioprine, prednisone, and 
Minnesota ALG. With this triple-drug thera-
py, they achieved better than 90% graft sur-
vival, compared to 74% with the proscribed 
cyclosporine-steroid combination; the results 
barely missed statistical significance. In a 
subset of the European trial reported from 
Birmingham, England, the I-year graft sur-
vival was almost identical (70%) in the experi-
mental and conventional groups, but the enor-
mous advantage in the cyclosporine arm was 
that about half of the successfully treated 
recipients were not being given steroids. In a 
Helsinki report, the I-year control and test 
groups both had 80% graft survival. 
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The importance of giving weight to the 
quality of life by avoiding excessive steroid 
treatment was most strongly emphasized in 
the descriptions of the randomized Australian 
trials in which cyclosporine alone was com-
pared to conventional azathioprine-predni-
sone treatment. Although the life survival 
curves of the grafts were about the same, with 
70% I-year cadaveric kidney function at 2 
years, the quality of life was better in the 
experimental series. 
In the United States, randomized trials of 
cadaveric transplantation in single centers 
were conducted by the Pittsburgh, Boston, 
Houston, and Minnesota teams. Because of 
the wide divergence of results between the 
experimental and conventional azathioprine-
prednisone groups, the trials in Pittsburgh and 
Houston had to be stopped. The trials have 
continued at the University of Minnesota for 
the simple reason that there has been no 
difference at that institution with cyclospo-
rine-steroid therapy versus treatment with 
azathioprine, prednisone, and ALG. The 
cadaveric graft survival has been in the 80% 
range, with a I-year patient mortality of 
about 10% in both conventional and test 
groups. 
Throughout their investigations of cyclo-
sporine and in the period preceding their use 
of this new drug, the Houston team has made 
a particular effort to stratify all of their 
recipients on the basis of preexisting immune 
reactivity. By so doing, they have been able to 
classify their recipients over the last several 
years into high, intermediate, and low immu-
nologic responders. The value of cyclosporine-
steroid therapy was particularly striking in 
the high-responder group; in the low-re-
sponder group, the results were already so 
good with conventional therapy that cyclo-
sporine was more a convenience than an over-
riding advantage. In discussing the Minnesota 
experience at one of the forum meetings, 
Kahan speculated that high responders may 
have been culled out by preoperative prepara-
tion with at least 10 transfusions; the conse-
quence would be to convert many high respon-
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ders to a non transplantable state because of 
stimulation of preformed antibodies. The 
transfusions plus the obligatory splenectomy 
in the Minnesota study could have edged those 
patients who made it through the full preoper-
ative preparation into the nonresponsive 
group. No one could really argue with this 
carefully thought-out "strategy" of transplan-
tation, but what was questioned was if this 
kind of pretransplant preparation was really 
going to be necessary or desirable in the 
future. The ability to treat patients efficiently 
and effectively without extensive preparation 
(including a major operation) before trans-
plantation may be especially important in 
patients who are at high risk because of 
advanced age or other adverse factors. Groth 
of Stockholm reported an outstanding series 
of cadaveric transplantations under cyclo-
sporine-steroid therapy in a group of patients 
who were 55 to more than 70 years old. The 
results were twice as good as in historical 
controls. 
A summary statement avoiding excessive 
enthusiasm as well as undue pessimism would 
have to note that the results with cyclosporine-
steroid therapy have never been inferior to 
those achieved by any of the investigating 
groups using their own version of conventional 
therapy for controls and that they usually 
have been superior. This in itself says a lot 
about the quality of the immunosuppression 
provided by cyclosporine-steroid therapy, 
since its effective use has required a major 
intellectual adjustment by those accustomed 
to the use of azathioprine and prednisone 
(with or without ALG). Nephrotoxicity has 
been the most serious side effect of cyclospo-
rine, meaning that a reduction in cyclosporine 
dosage is frequently the most appropriate 
response to a secondary decline in renal func-
tion, rather than the reflex increase in steroid 
doses that has been so often called for in the 
past. 
The role of plasma or blood cyclosporine 
analysis in reaching a final dose under such 
circumstances is by no means clear. All 
groups are trying to use pharmacologic moni-
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toring, but Ferguson, in a study of 70 consecu-
tive Minnesota cases, found no correlation 
whatever between blood cyclosporine levels 
and nephrotoxicity. The Houston and London, 
Ontario, groups were in sharp disagreement. 
Yet all observers conceded that the blood-
level determinations have permitted identifi-
cation of specific situations in which the 
trough levels of cyclosporine were either much 
too high or surprisingly low. It is hard to 
believe that blood or plasma analysis will not 
have some value, at least in isolated cases. At 
the same time, it is equally clear that good 
clinical management can be carried out with-
out this luxury. 
It has always been comforting for clinicians 
to turn to the pathologist for final arbitration 
of disputes about the pathogenesis of compli-
cations. These roles have almost been reversed 
in trying to clearly distinguish cyclosporine 
nephrotoxicity and homograft rejection. Ef-
forts were reported by the Minnesota group to 
categorize the histologic findings in subnor-
mally functioning kidney grafts according to 
the clinical response to steroid therapy. Abso-
lutely reliable guidelines for adjustment of 
therapy have not been delineated by this 
approach. K. A. Porter of London looked at a 
number of renal graft biopsies from our early 
cyclosporine experience. Rejection was com-
mon, but its features differed from those seen 
with conventional immunosuppression only in 
a somewhat greater proportion of the eosino-
phils in the infiltrating cells. In kidneys exam-
ined from both heart and hepatic recipients, 
Porter could not find specific lesions of drug 
nephrotoxicity. Discussion of this problem is 
certain to enliven clinical and pathologic con-
ferences for years to come. 
Since the beginning of clinical trials in 
renal transplantation, the unquestioned neph-
rotoxicity has explained higher average levels 
of serum creatinine in cyclosporine-treated 
kidney recipients than in successfully treated 
controls. Even if the creatinine is high early 
after transplantation (as high as the 3-4 mg/ 
dl range), there is no urgency to reduce the 
cyclosporine dose if the patient feels well and 
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if the abnormal creatinine is not rising. Our 
own policy has been to try to invest about 2 
months of maximum cyclosporine dosage dur-
ing the induction of graft acceptance. A pre-
mature pullback of dosage can lead to rejec-
tion. The coexistence of nephrotoxicity and 
rejection suggested by us some time ago has 
been supported strongly by the Houston, 
Stockholm, and Minnesota clinicians with evi-
dence presented at this meeting. Personally, I 
believe that the extensive and beautiful Min-
nesota pathology studies could be interpreted 
as an expression of this dual problem. Anyone 
using cyclosporine at this time should care-
fully read the therapeutic strategies that have 
been developed by the various groups includ-
ing ours to accommodate both possibilities of 
rejection and nephrotoxicity. 
The other side effects of cyclosporine were 
mentioned frequently throughout the meet-
ing. The hypertension and hyperkalemia that 
have been subjects of separate papers are 
certainly manifestations of the drug's nephro-
toxicity. Hepatotoxicity, hirsutism, tremors 
(and even possibly seizures), and gingival 
hyperplasia have been reduced or relieved by 
dose reduction. When life-threatening infec-
tions have appeared in any large numbers 
under cyclosporine and steroids, the usual 
conclusion has been that overimmunosuppres-
sion with one or the other of the two agents has 
been responsible. In earlier reports from the 
University of Minnesota, it appeared that 
infections with bacteria, fungi, protozoa, and 
viruses were all markedly less under cyclospo-
rine-steroid therapy than under conventional 
immunosuppression, but Najarian reported 
that this advantage in Minneapolis had been 
narrowed if not lost in their later experience, 
with the striking exception of the cytomegalo-
virus syndromes. The bewildering cross sec-
tion of infections and how the patterns dif-
fered with different kinds of transplantations 
in Pittsburgh were described by Ho. 
A striking observation in almost all of the 
renal trials has been the remarkably good 
results in cadaveric renal retransplantation, 
even including patients with widely reacting 
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T -warm antibodies or with a history of aggres-
sive rejection of multiple previous organs. In 
the past, the justification for trying too hard to 
retain kidney grafts (with a resulting high 
mortality) has been the clouded future of 
recipients who rejected kidneys and then 
faced cadaveric retransplantation. That justi-
fication does not seem to exist anymore using 
cyclosporine-steroid therapy. As that new fact 
of life becomes broadly appreciated, the 1-
year patient mortality after primary trans-
plantation is apt to reach the 5% or lower level 
that will represent an irreducible minimum 
imposed by disease of other organ systems. 
It would be easy to spend this entire sum-
mary talking about renal transplantation-
and with some justification because of the 
broad applicability of the lessons being 
learned. The ripple effect certainly has been 
felt with liver transplantation, which (under 
cyclosporine) has become about twice as safe 
as in the past. The great improvement made 
possible with cyclosporine has increased the 
frequency and boldness with which liver 
replacement has been carried out, and now the 
prospect of escalating this advantage into 
other improvements (including technical) is a 
very bright one. Since the liver is the major 
site of metabolism of cyclosporine, all kinds of 
problems could easily be visualized about dose 
control. The major prediction in liver recip-
ients could be of astronomical overdosage, but 
in fact the opposite has occurred, in that 
unreliable absorption of the drug has been the 
most consistent problem with consequent 
underdosage. Our liver recipients are now 
receiving double-route cyclosporine therapy, 
beginning with intravenous doses and con-
tinuing this intravenously for at least 2 weeks, 
long after the resumption of an oral diet and 
oral cyclosporine. The changeover from the 
double-route administration to an oral dose 
alone can be greatly aided by the systematic 
measurement of blood cyclosporine levels. 
The several groups who discussed their experi-
ence with liver transplantation under cyclo-
sporine did not carry out randomized trials, 
and it is unlikely that this will ever be done. 
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The same lack of enthusiasm about ran-
domized trials in cardiac transplantation was 
evident. The Stanford heart transplanters 
have achieved a I-year survival of 80%, with a 
2-year actuarial survival in excess of 70%. The 
fact that other groups have been able to do 
almost as well in Pittsburgh, Cambridge, and 
Houston means that pressure to expand this 
type of clinical service is bound to increase. At 
Stanford, the more complex heart-lung trans-
plantations, which were not previously possi-
ble either in experimental animals or humans, 
have been successful in 8/11 patients who 
have been followed for 2 months to 2 years. In 
Pittsburgh, the survival record with heart-
lung transplantation has been 3/5. Shumway 
has speculated that isolated lung transplanta-
tions may be infinitely more difficult than 
composite thoracic organ transplantation, but 
the merits of that argument aside, Veith has 
accomplished single-lung transplantation in 
dogs using cyclosporine, although he has not 
yet succeeded in human patients. 
With cyclosporine, it will be surprising if 
major advances cannot be made in pancreas 
transplantation. Sutherland pointed out that 
this has not been achieved at the University of 
Minnesota. The same conclusion was reached 
by Dubernard of Lyon, but Groth has had 
successes with half of his cadaveric segmental 
pancreas transplantations in Stockholm dur-
ing the last year. The prospect of using the 
pancreatico-duodenal-jejunal composite 
grafts now that better immunosuppression is 
available was raised, and two successful cases 
with perfect results after 1 and 3 months were 
presented from Pittsburgh. Parenthetically, 
both of these recipients are carrying about 3 ft 
of donor small intestine. Several groups are 
poised to attempt intestinal transplantation in 
humans, a procedure that has been success-
fully carried out in mongrel dogs with survival 
of almost 2 years. 
Most of what I have summarized has come 
from recent trials. In chronic survivors after 
various kinds of transplantation, the question 
keeps coming up of the possible desirability of 
early or late conversion from cyclosporine to 
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maintenance therapy with azathioprine. This 
will be necessary in some patients, but at what 
frequency is debatable. In our renal graft 
recipients treated 3 years ago, the conversion 
rate was about 20%, and in this subgroup, 
40% subsequently rejected their grafts, as 
Klintmalm has reported. Our switch rate has 
steadily declined; it is now about 5%. The 
opposite trend is identifiable in the data pre-
sented from Minnesota, and, of course, all 
patients at Oxford have been converted at 90 
days. 
In the recipients of hearts and livers, the 
predominant conversion has been in the other 
direction-from conventional azathioprine-
prednisone therapy to cyclosporine. Typically, 
a patient whose survival with one of these 
organs years after transplantation depends on 
unacceptably high steroid doses has been 
switched to cyclosporine and the prednisone 
has been discontinued. We have carried out 
this change in half a dozen liver recipients. 
The hepatic function has not deteriorated in 
any case, and in most it has actually improved. 
The advantages and dangers of this switch-
over were discussed in one full session and 
cannot be adequately summarized here. It 
should be noted that there is a potential risk of 
mixing drugs, especially in the early postoper-
ative period, as was exemplified by the fright-
ening experience in Lyon, which resulted in a 
nearly 50% incidence of lymphoproliferative 
complications in a small series of patients 
given azathioprine, prednisone, ALG, and 
cyclosporine, in that general order. 
Except for this experience, the incidence of 
de novo malignancies under cycIosporine-
steroid therapy has been acceptable. It looks 
as if the incidence of Iymphoproliferative 
complications is going to be less than 2%, but 
the implications of even that figure are rela-
tively bland. Rosenthal reported that the sim-
ple discontinuance or reduction of immuno-
suppression (both cyclosporine and steroid 
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doses) in patients with so-called lymphomas 
resulted in the involution and disappearance 
of the lesions. Most of the lymphomas seen 
under immunosuppression are probably asso-
ciated with (or caused by) the Epstein-Barr 
virus. 
Where cyclosporine will fit in the future of 
bone marrow transplantation is difficult to 
predict. The cross section of side effects of 
cyclosporine in bone marrow recipients has 
been very broad, and almost invariably some 
other potentially toxic drug was thought to 
have had an adverse interaction with the 
cyclosporine. The most common culprits were 
antibiotics, especially those used for their 
antifungal effect. It may be that cyclosporine 
will not influence practices in bone marrow 
transplantation to the extent that looks proba-
ble with solid organs, but it would be less than 
fair not to point out that the pioneering obser-
vations of Powles about the control of graft-
versus-host reactions in humans made 4 years 
ago have been confirmed under a number of 
clinical circumstances. 
So much material was presented at this 
conference and with such immediate clinical 
applicability that I find it impossible to do 
justice to the conference and to its partici-
pants in this summary. The conference came 
at a uniquely propitious moment, since cyclo-
sporine will become available to all clinicians 
within the next few weeks or months. I believe 
that we of the transplantation community owe 
a unique debt to the fathers of cyclosporine, 
Jean Borel, David White, and Roy Caine, 
(who could not be here); to those highly 
responsible men and women in the Sandoz 
Corporation who have permitted and encour-
aged us to look at the blemishes as well as the 
perfections of cyclosporine; and to the master-
ful host of this conference, Barry Kahan, who, 
as I have remarked to others, is one of the 
great scientist-surgeons in the world today. 
